摘要
实验证明N-甲基-D-天冬氨酸(NMDA)受体的激活与痛阈降低和中枢敏感化有关,全身或鞘内应用NMDA拮抗剂可抑制伤害性反应,拮抗痛阈降低和防止或逆转中枢敏感化;NMDA受体非竞争性拮抗剂氯胺酮在临床已用于急慢性疼痛的治疗,关于其在超前镇痛的作用基础与临床作了大量研究,但结果并不一致;本文就其最新临床研究进展予以综述。
The experiments have proved that the activation of N-methyl-Daspartate （NMDA）receptor was responsible for the decreasion of pain threshold and central sensitization . NMDA receptor antagonist that was administered systemically or intrathecally can inhibit nociceptive effect.competitive inhibit the deereasion of pain threshoht and prevent or reverse central sensitization . Ketamine is a NMDA receptor noncompetitive antagonist, which has been administered clinically to treat acute or chronic pain syndrome. A lot of study have been carried about its effect of preemptive analgesia, but we have differcnt results. Su this article summarized the progress about this drug in clinical research in recent years.
出处
《医学综述》
2006年第4期242-244,共3页
Medical Recapitulate
关键词
镇痛
超前镇痛
氯胺酮
Analgesia
Preemptive analgesia
Ketamine
